A Randomized, Open-label Trial Comparing Telbivudine vs, Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Who Have Achieved Serum HBV DNA Undetectability by Preceding Entecavir Treatment

Trial Profile

A Randomized, Open-label Trial Comparing Telbivudine vs, Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Who Have Achieved Serum HBV DNA Undetectability by Preceding Entecavir Treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2017

At a glance

  • Drugs Telbivudine (Primary) ; Entecavir
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms TERESA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Jan 2017 Primary endpoint (HBsAg titer at 48 weeks) has not been met according to the results published in the BMC Gastroenterology.
    • 19 Jan 2017 Results published in the BMC Gastroenterology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top